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ctivating mutations in ﬁbroblast growth factor
receptor 2 (FGFR2) cause several craniosynostosis
syndromes by affecting the proliferation and
differentiation of osteoblasts, which form the calvarial
bones. Osteoblasts respond to FGF with increased prolif-
eration and inhibition of differentiation. We analyzed the
gene expression proﬁles of osteoblasts expressing FGFR2
activating mutations (C342Y or S252W) and found a
striking down-regulation of the expression of many Wnt
target genes and a concomitant induction of the tran-
scription factor Sox2. Most of these changes could be
reproduced by treatment of osteoblasts with exogenous
A
 
FGF. Wnt signals promote osteoblast function and regulate
bone mass. Sox2 is expressed in calvarial osteoblasts in
vivo and we show that constitutive expression of Sox2
inhibits osteoblast differentiation and causes down-
regulation of the expression of numerous Wnt target
genes. Sox2 associates with 
 
 
 
-catenin in osteoblasts and
can inhibit the activity of a Wnt responsive reporter
plasmid through its COOH-terminal domain. Our results
indicate that FGF signaling could control many aspects of
osteoblast differentiation through induction of Sox2 and
regulation of the Wnt–
 
 
 
-catenin pathway.
 
Introduction
 
Human and mouse genetic studies have established that FGF
signaling plays an essential role in skeletal development.
Several human autosomal dominant bone disorders, such as
dwarfism and craniosynostosis, are caused by missense muta-
tions in FGF receptors (FGFR1–3), which are expressed in
osteoblasts and chondrocytes, the two major cell types respon-
sible for bone formation. These mutations cause misregulated
tyrosine kinase receptor activity by producing hypersensitive
receptors that respond to lower concentrations of ligand or
constitutively active receptors that signal in the absence of FGF
(Ornitz and Marie, 2002).
The formation of skeletal elements such as bone and carti-
lage is controlled by a complex network of signaling molecules
that control the differentiation of multipotent mesenchymal
cells into osteoblasts and chondrocytes, and then regulate their
proliferation and subsequent terminal differentiation (Karsenty
and Wagner, 2002). The direct conversion of mesenchymal
tissue into bone without prior formation of cartilage, termed
intramembranous ossification, is performed directly by osteo-
blasts to form the flat bones of the skull vault. Osteoblast
differentiation takes place at the bone margins, or osteogenic
fronts, where the surrounding mesenchymal/osteoprogenitor
cells are recruited to differentiate into bone-forming osteo-
blasts. Before birth, calvarial bones approximate each other
with sutures forming between the bone margins (Bonaventure
and El Ghouzzi, 2003). Craniosynostosis, or premature suture
closure, is a defining feature in craniofacial skeletal disorders
such as Crouzon (CR), Apert (AP), Pfeiffer, and Jackson-
Weiss syndromes, which are due to activating mutations in
FGFR2 (Ornitz and Marie, 2002).
Craniosynostosis in patients carrying activating FGFR1
or FGFR2 mutations has often been interpreted as reflecting
premature bone formation due to increased osteoblast differen-
tiation (Lomri et al., 1998; Marie, 2003). However, the response
of osteoblast to FGF in culture does not support such views.
We and others have shown that FGFs promote proliferation of
immature osteoblast/osteoprogenitor cells (Debiais et al., 1998;
Mansukhani et al., 2000) and that constitutive FGF signaling
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inhibits osteoblastic differentiation and dramatically increases
apoptosis when cells are exposed to differentiating conditions
(Mansukhani et al., 2000; Nakayama et al., 2003). Human stud-
ies also reveal that the bone of patients with craniosynostosis
syndrome is often more brittle and thinner than nonaffected
bone (Tholpady et al., 2004). Furthermore, recent studies on a
mouse model of AP craniosynostosis showed reduced, rather
than increased, bone mass in the skull, no evidence of in-
creased expression of differentiation genes, and a highly in-
creased rate of osteoblast apoptosis in or around the cranial su-
tures (Chen et al., 2003). Thus, to further understand the
mechanisms underlying the response to FGF of osteoblasts and
the results of constitutive FGF oversignaling in these cells, we
have compared by microarray analysis the pattern of gene ex-
pression in proliferating and in differentiating conditions of an
osteoblastic cell line (OB1; Mansukhani et al., 2000) with that
of OB1 cells, which express the two most common FGFR2 mu-
tations found in CR (C342Y) or AP (S252W) syndromes.
Among the many significant gene expression changes de-
tected in AP and CR cells, we observed a striking down-regula-
tion of many genes that have been identified as targets of Wnt
signaling. Recent papers have uncovered an important role for
Wnt signaling in promoting osteoblast function and bone for-
mation (Harada and Rodan, 2003). In humans, inactivating
mutations in the Wnt coreceptor LRP5 cause osteoporosis/
pseudoglioma, a syndrome characterized by reduced bone den-
sity (Gong et al., 2001). Conversely, activating LRP5 muta-
tions are linked to autosomally dominant high bone mass syn-
dromes, which do not result from reduced bone resorption
(Boyden et al., 2002; Little et al., 2002; Babij et al., 2003).
Figure 1. Gene expression changes in OB1,
Crouzon (CR), and Apert (AP) cells. (A) Level of
expression of selected genes normalized to
OB1 in growing and differentiating (diff) con-
ditions. The average percentage of cells positive
for ALP in each set is indicated at the top.
Green, down-regulation in AP and CR; gold,
up-regulation in AP and CR; red underlined,
Wnt target genes. Microarray analysis was
performed as detailed in Materials and methods.
0.00 represents  0.01. (B) Semi-quantitative
RT-PCR analysis on OB1, CR, and AP cells.
The amount of PCR product obtained is visual-
ized by ethidium bromide stain. 
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Mice lacking LRP5 develop low bone mass and osteoporosis,
and LRP5 null-osteoblasts display reduced proliferation and
differentiation (Kato et al., 2002). Thus, down-regulation of
Wnt signaling could be a mechanism by which FGFs inhibit
osteoblast differentiation.
In this paper, we show that down-regulation of Wnt target
genes is observed both in osteoblasts expressing activated
FGFR2 and in osteoblasts treated with exogenous FGF. We
also identify a strong induction of expression of Sox2, a mem-
ber of the high mobility group (HMG) domain Sox family of
transcription factors, whose expression was previously thought
to be limited to very early developmental stages and to the neu-
ronal lineage. Ectopic expression of Sox2 is sufficient to inhibit
osteoblast differentiation. We show that Sox2 can interfere
with the transcriptional activity of 
 
 
 
-catenin/lymphoid en-
hancer factor (LEF), the classical effectors of Wnt signaling,
and that it associates with 
 
 
 
-catenin in osteoblasts. Thus, Sox2
induction and antagonism of Wnt signaling play an important
role in the response of osteoblasts to FGF signals, and Sox2 in-
duction is responsible, at least in part, for down-regulation of
Wnt target genes. Down-regulation of Wnt target genes by
FGF signaling could provide an explanation for the inhibition
of osteoblast differentiation induced by FGF.
 
Results
 
Gene expression profiles of OB1 
osteoblasts and OB1 cells expressing 
FGFR2/AP and FGFR2/CR mutations
 
We have previously described the isolation and characteriza-
tion of the murine OB1 osteoblast cell line, which was derived
from calvarial osteoblasts by immortalization with Polyoma
large T-antigen. OB1 cells are spindle-shaped immature os-
teoblasts that mature to a larger cuboidal phenotype when
differentiation is induced. Alkaline phosphatase (ALP) and os-
teocalcin levels are initially undetectable but are steadily up-
regulated during differentiation (Mansukhani et al., 2000).
Treatment of OB1 with FGF increases proliferation of imma-
ture cells, but differentiation is blocked and apoptosis is in-
duced when cells exposed to FGF are placed under differentiat-
ing conditions. We have also shown that expression of two
activating FGFR2 mutations, C342Y, found in CR syndrome,
and S252W, found in AP syndrome, increase proliferation and
block differentiation of OB1 cells (Mansukhani et al., 2000).
When these cells are exposed to differentiating conditions,
apoptosis is greatly enhanced.
To further examine the effects of constitutive FGF signal-
ing in osteoblasts, we used microarray analysis to compare the
program of gene expression in proliferating OB1 cells with that
of OB1 cells expressing the FGFR2 mutations C342Y (CR) and
S252W (AP). We also examined the gene expression patterns in
the three cell types after they were induced to differentiate for
7 d. RNA was prepared from three independent samples of pro-
liferating or differentiating cells and converted into biotinylated
cRNA. Samples were hybridized to mouse Affymetrix U74Av2
microarray chips containing probes for 
 
 
 
9,400 genes and ESTs
and the data was analyzed as described in Materials and methods.
Of the 
 
 
 
7,800 genes that were expressed in at least one
sample, 80% showed no significant change between the OB1,
AP, and CR samples. Greater than 2.5-fold changes were found
in 282 down-regulated and 205 up-regulated genes in the AP
and CR cells compared with OB1. For most of these genes the
changes were greater in AP than in the CR cells, probably be-
cause of a higher degree of FGF signaling in the AP cells
(Mansukhani et al., 2000). Several interesting changes were
noted, some of which are shown in Fig. 1.
 
Differentiation genes. 
 
Staining for ALP showed
that AP and CR cells do not differentiate, whereas OB1 cells
increase ALP expression (up to 15%) upon differentiation
(Fig. 1 A). Most genes known to be up- or down-regulated dur-
ing osteoblast differentiation (Beck et al., 2001; Garcia et al.,
2002; Qi et al., 2003) were regulated as expected in OB1 cells
differentiated for 7 d, but the changes were blocked or attenu-
ated in AP or CR cells. Matrix genes such as osf-2, osteocalcin,
fibromodulin, and cadherin-11 and the transcription factor
C/EBP
 
 
 
 and BMP4, whose expression increased during OB1
differentiation, had a lower basal level of expression in AP and
CR cells and were not induced or poorly induced in differenti-
ating conditions (Fig. 1 A). PCNA and thymidine kinase ex-
pression was down-regulated upon differentiation in OB1 cells
but remained high in AP and CR cells. Unexpectedly, osteogly-
cin and IGFBP3, which are up-regulated upon differentiation in
OB1 cells, have higher basal levels in AP and CR cells. How-
ever, the extent of their induction under differentiating condi-
tions was reduced.
 
Apoptosis-related genes. 
 
CR and AP cells show
a high rate of apoptosis when placed under differentiating con-
ditions. The expression of GAS6, a ligand for the AXL/ARK
receptor, whose main function is to protect from apoptosis
(Bellosta et al., 1997), is down-regulated in these cells both in
growing or differentiation conditions. This is also the case for
the WISP-1 gene, which is known to protect from apoptosis
(Su et al., 2002), whereas the proapoptotic factors Bid and
caspase-6 are up-regulated.
 
Signaling molecules. 
 
Components of several sig-
naling pathways such as IGFs and BMPs, which are known to
control bone development, were up- or down-regulated in the
AP and CR cells. It has been suggested by us and others that
FGFs antagonize the differentiation-inducing signals of BMPs
(Minina et al., 2002; Bellosta et al., 2003). This suggestion is
supported by the lower expression of BMP target genes such as
noggin, d1 
 
 
 
 2, osf-2, decorin, and fmo1 (Vaes et al., 2002) in
the AP and CR cells.
 
Transcription factors. 
 
Several transcription fac-
tors that play a role in craniofacial development (msx2, hmxl,
dlx2, engrailed, and Pitx2) were down-regulated in the mutant
receptor-expressing cells (Fig. 1 A). The strongest up-regulated
gene in the AP and CR cells was the HMG-box–containing
transcription factor Sox2. This finding was unexpected because
Sox2 expression is usually associated with undifferentiated
multipotent cells, such as ES and EC cells (Yuan et al., 1995).
It has also been shown to maintain the undifferentiated state in
neural progenitor cells and at later stages is a marker of the ner-
vous system (Avilion et al., 2003; Bylund et al., 2003). As will 
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be discussed later, several data suggest that Sox2 induction
may be a mediator of the FGF response in osteoblasts.
 
Wnt target genes. 
 
We noted that a significant
number of Wnt target genes (www.stanford.edu/~rnusse/
wntwindow.html), whether they encoded transcription factors,
signaling molecules, or matrix proteins, are down-regulated in
AP and CR cells (Fig. 1 A, underlined red). Although the extent
of down-regulation was variable, this trend was of particular in-
terest because of the genetic evidence linking Wnt signals with
increased bone mass. The Wnts are a large family of growth fac-
tors that signal by interacting with their receptors, consisting of
the Frizzled family of seven transmembrane proteins and the es-
sential coreceptors of the low density lipoprotein receptor-
related proteins (LRP5 and LRP6). In the absence of Wnt sig-
nals, GSK3
 
 
 
 constitutively phosphorylates 
 
 
 
-catenin, which is
then modified by ubiquitination and degraded. Activation of
Wnt receptors blocks the GSK3
 
 
 
 activity and degradation of
 
 
 
-catenin, which is translocated to the nucleus where it interacts
with members of the T cell factor (TCF)/LEF family of HMG-
domain transcription factors to activate Wnt target gene tran-
scription (Cadigan and Nusse, 1997; Eastman and Grosschedl,
1999). Approximately 40% (18 genes) of the known Wnt target
genes that are present on the chip and that are expressed in OB1
cells were down-regulated in the AP or CR cells. In some cases,
such as Id2 and osteocalcin, which have very low expression in
undifferentiated OB1 cells, the down-regulation was only evi-
dent when cells were in differentiating conditions (Fig. 1).
Several of the changes seen in the microarray experiment
were validated by Northern blotting or by RT-PCR analysis
on selected genes. Fig. 1 B shows that the Wnt target genes
Wisp1, Wisp2, dlx2, and msx2 were down-regulated in CR and
AP cells as was the Wnt receptor frizzled-4 (Fig. 1 B, Fzd4). In
contrast, as indicated by the microarray analysis, the transcrip-
tion factor Sox2 was strongly up-regulated (Fig. 1 B). We
found that the level of total 
 
 
 
-catenin mRNA remained con-
stant in all samples and during differentiation and was used as
an internal control in subsequent real-time PCR experiments.
 
Wnt target genes are down-regulated by 
exogenous FGF in osteoblasts
 
Among the changes in gene expression observed in the AP and
CR cells, we found down-regulation of Wnt target genes and
up-regulation of Sox2 particularly striking. Wnt signaling has
been recently shown to promote osteoblast differentiation and
function (Harada and Rodan, 2003), and other members of the
Sox family have been shown to interfere with Wnt signaling in
 
Xenopus laevis 
 
by binding to 
 
 
 
-catenin and inhibiting the tran-
scriptional activity of the 
 
 
 
-catenin–TCF/LEF complex (Zorn
et al., 1999). To demonstrate that such changes in gene expres-
sion were not due to clonal selection in our AP or CR lines, or
specific effects of mutant FGFR2 forms, we treated OB1 cells
with exogenous FGF1 for 1, 3, 6, 10, and 24 h and performed
microarray analysis on duplicate RNA samples as before. The
details of this analysis will be described elsewhere; however,
the great majority of genes whose expression was elevated or
reduced in the AP and CR cells relative to OB1 were similarly
regulated by exogenous FGF treatment. Of the 18 Wnt target
genes that were down-regulated in the AP and CR cells (Fig. 1
A), all but 4 (msx2, pitx2, BMP4, and IGF-1) were also down-
regulated by exogenous FGF treatment of OB1 cells. Further-
more, three additional Wnt target genes, Frizzled-1, sfrp-2, and
islr, that were unchanged in AP and CR cells were down-regu-
lated by exogenous FGF, whereas expression of the Wnt tar-
gets c-myc, fra-1, and twist, which were not down-regulated in
AP and CR cells, were all transiently induced early by FGF
treatment (unpublished data).
The down-regulation of the expression of Wnt target genes
dlx2, engrailed-1, cadherin-11, wisp1, and wisp2 was confirmed
by real-time RT-PCR analysis (Fig. 2). Fig. 2 also shows that
Sox2 expression is strongly induced by 1 h of FGF treatment,
before significant down-regulation of Wnt target genes.
 
Sox2 is induced by FGF in osteoblasts
 
To further analyze the FGF-mediated induction of Sox2 in os-
teoblasts, we treated OB1, AP, and CR cells with FGF1 for var-
ious times and examined the expression of Sox2 mRNA by
Northern analysis. Fig. 3 A shows that Sox2 mRNA was
strongly induced by FGF treatment in the OB1 cells, whereas
the induction is modest in AP and CR cells that have a high
basal level. Treatment of AP cells with an inhibitor of FGFR
kinase activity (SU5402) drastically reduced the level of Sox2
mRNA, indicating that Sox2 expression is dependent on FGF
signaling (Fig. 3 B). We examined whether or not this response
was specific to osteoblasts. The induction of Sox2 mRNA by
Figure 2. Real-time RT-PCR on time course of
FGF. OB1 cells were treated with 10 ng/ml
FGF1 for 1, 3, 6, 10, or 24 h. Each indicated
cDNA was amplified by real-time PCR using
specific primers and SYBR green for PCR prod-
uct detection. The value of 100% was given to
each OB1 untreated (0 h) sample (black
bars). The experiment was performed in
quadruplicate and the average   SD is shown. 
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FGF was not observed in NIH3T3 fibroblasts (Fig. 3 A), RCS
chondrocytes, or in mouse embryo fibroblasts (not depicted).
To ensure that the specificity of Sox2 induction was not a pecu-
liarity of OB1 cells, we also determined that Sox2 mRNA is in-
duced by FGF treatment of primary murine calvarial osteo-
blasts (Fig. 3 C).
Fig. 3 D shows that also Sox2 protein is expressed in
OB1 osteoblasts treated with FGF, whereas AP cells have a
high level even in the absence of FGF. Sox2 protein was also
induced by FGF in OB5 cells, a spontaneously immortalized
osteoblastic cell line derived from p53
 
 
 
/
 
 
 
 murine calvaria
(Fig. 3 D). FGF treatment also induced Sox2 in both U2OS os-
teosarcoma cells and in murine primary calvarial osteoblasts
(Fig. 3 E). These data clearly show that Sox2 is an FGF-induc-
ible gene in osteoblasts that is constitutively expressed in os-
teoblasts expressing activated FGFR.
We performed in situ hybridization on calvarial sections
of P1 mice using Sox2 as a probe. Fig. 3 F shows that Sox2 ex-
pression is already detected in osteoblasts at the osteogenic
bone fronts, where FGFR2 expression is high (Iseki et al.,
1999). Thus, the in vivo expression pattern of Sox2 strongly in-
dicates that the in vitro findings are of physiological relevance.
 
Constitutive expression of Sox2 blocks 
osteoblast differentiation
 
To test whether Sox2 could interfere with osteoblast differenti-
ation, we transfected OB1 cells with a murine Sox2 expression
plasmid and isolated individual hygromycin-resistant clones as
well as pools of resistant cells. Clones or pools were tested for
their ability to differentiate and compared with a pool trans-
fected with the empty vector (OB1/vector). Cells were plated
and stained after 2 and 25 d for ALP (Fig. 4 A). Although at
day 2 all the cells expressed very little ALP, after 25 d much
fewer ALP-positive cells were visible in the Sox2-expressing
cells relative to the control (Fig. 4 A). OB1/vector cells dis-
played the multilayering typical of differentiating cells and
stained strongly for ALP. OB1/Sox2-pool cells that have a low
level of Sox2 show much less differentiation than OB1/vector
at day 25. The OB1/Sox2-cl2 cells that express high levels of
Sox2 mRNA do not express ALP, do not form multilayers, and
maintain the phenotype of undifferentiated cells (Fig. 4 A). In
other clones that expressed relatively high levels of Sox2 pro-
tein, the block in differentiation was evident as measured by
ALP staining (Fig. 4 B).
We also tested the ability of Sox2 to block differentiation
of OB5 osteoblasts that lack Polyoma Large T-antigen. OB5
cells differentiate more uniformly than OB1 cells, and mineral-
ization of the matrix can be seen by 7–10 d of differentiation
upon staining with Alizarin red. Fig. 4 C shows that also in
OB5 cells, expression of Sox2 delays the appearance of ALP
and mineralization is not detected even at 16 d. Thus the block
to osteoblast differentiation induced by constitutive FGF sig-
nals can be reproduced by ectopic expression of the FGF-induc-
ible gene Sox2.
We used microarray analysis to determine the expression
of genes known to be regulated during osteoblast differentia-
tion (Beck et al., 2001; Garcia et al., 2002; Qi et al., 2003). We
chose the OB1/Sox2#16 clone because it expressed the highest
level of Sox2 (Fig. 4 B). The analysis was done, as described in
Materials and methods, on cRNA prepared from duplicate sam-
ples of OB1/Sox2#16 that were either untreated or maintained
in differentiation medium for 7 d. The data from this analysis
was normalized against the data from OB1 cells (Table I).
Table I shows that the expression of most genes that are
strongly up or down-regulated during OB1 differentiation was
modestly altered or unchanged under differentiating conditions
in Sox2#16 cells. Osteocalcin, C/EBP
 
 
 
, and IGFBP3 were
strongly induced in differentiating OB1 cells, but were not in-
Figure 3. Expression of Sox2 in osteoblasts.
(A) mRNA for Sox2 is induced by FGF. OB1,
AP, CR, or NIH3T3 cells were grown in the
presence of serum and treated with 10 ng/ml
FGF1 and 5  g/ml heparin for the indicated
times and analyzed by Northern blot with a
32P-labeled Sox2 cDNA (Yuan et al., 1995).
Gapdh probe was used as a control. (B)
Northern analysis of Sox2 expression in AP
cells treated with DMSO (D) or SU5402 (SU)
for 24 h. (C) Sox2 mRNA is induced by FGF1
in murine primary calvarial osteoblasts. (D
and E) Western analysis of Sox2 induction by
24-h FGF1 treatment ( ) in OB1 and OB5
osteoblasts and in U2OS and primary calvarial
osteoblasts. (F) Serial sagittal sections through
the coronal suture of a wild-type mouse at P1
is shown (frontal bone at left, parietal bone at
right; of, osteogenic front). ALP expression
was detected by enzymatic histochemistry,
whereas Sox2 and Osteopontin RNA expression
was detected by in situ hybridization using
anti-sense riboprobes labeled with digoxigenin-
UTP. ALP is present in immature and maturing
osteoblasts, Sox2 expression is restricted to
the immature osteoblasts of the osteogenic
fronts. Osteopontin is expressed in maturing
osteoblasts. 
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duced in Sox2#16 cells. Decorin and fibromodulin, which are
matrix genes that were increased during OB1 differentiation,
were strongly reduced in Sox2#16 cells under proliferation and
differentiation conditions. Cadherin-11, osteomodulin, osf-2,
and BMP-4 were induced in differentiation medium much
more weakly in Sox2#16 cells than in the control OB1 cells.
Early induced genes (c-fos, Junb, Krox-20, and Krox-24) and S
phase genes such as PCNA and thymidine kinase, which are
down-regulated in differentiation in primary osteoblasts and in
OB1 cells, were not down-regulated in Sox2#16 cells. Most of
these changes had also been observed in the CR and AP cells.
Thus, constitutive expression of Sox2 can, like FGF signaling,
block osteoblast differentiation as measured by morphological
changes, by staining for ALP and mineralization, and by the
level of expression of differentiation genes.
 
Constitutive expression of Sox2 down-
regulates Wnt signaling
 
The down-regulation of several Wnt target genes together with
the strong induction of Sox2 in the AP and CR cells, as well as
by FGF treatment of OB1 cells, suggested the hypothesis that
FGF may be interfering with Wnt signals in osteoblasts via in-
creased levels of Sox2. Furthermore, because Sox2 expression
blocks differentiation and Wnt signals promote differentiation,
we reasoned that Sox2 may block differentiation via the down-
regulation of Wnt signaling. We have seen that treatment of
OB1 with LiCl, which mimics the activation of Wnt signals by
inhibiting GSK3 activity, increases ALP staining. In fact, LiCl
is also able to induce ALP in AP cells and enhance mineraliza-
tion in OB5 cells (Figs. S1 and S2, available at http://www.jcb.
org/cgi/content/full/jcb.200409182/DC1). These, along with ge-
netic data, indicate that FGF and Wnt signals have opposing ef-
fects in osteoblasts.
Therefore, we used the microarray analysis described in
the previous section to examine the expression of Wnt target
genes in Sox2#16 cells. Fig. 5 A shows that out of 18 Wnt target
genes in Fig. 1 A that were down-regulated in AP or CR cells,
12 were also down-regulated in the Sox2#16 cells. It is interest-
ing to note that the expression of the Wnt target gene fra-1,
which was up-regulated in the AP or CR cells because this gene
is a direct FGF target, was unchanged in the Sox2-expressing
osteoblasts, whereas the Wnt targets jun and twist, which were
Figure 4. Sox2 expression blocks osteoblast
differentiation. (A) 10
5 cells per well of OB1/
vector and OB1/Sox2-cl2 and OB1/Sox2-
pool cells were plated in 6-well plates and
placed in differentiation medium. Plates were
stained for alkaline phosphatase (ALP) expres-
sion (purple-brown) on the indicated days. (B)
Inhibition of ALP up-regulation upon differenti-
ation (left) is evident in some OB1/Sox2
clones expressing Sox2 protein (right). White
lines indicate that intervening lanes have been
spliced out. (C) OB5 and OB5/Sox2 cells
were seeded at 10
5 cells per plate and kept
in differentiation medium. On the indicated
days, cells were stained for ALP (purple) and
for mineralization with Alizarin red (red). 
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unchanged in AP and CR cells, are down-regulated in Sox2#16
cells (Fig. 5 A). Some of the Wnt target genes whose expression
is not changed in Sox2#16 cells were also not strongly down-
regulated in the AP and CR cells (BMP-4 and noggin). The
validity of the microarray data was verified by performing real-
time RT-PCR of a few strongly down-regulated Wnt target
genes (Fig. 5 B). Thus, constitutive Sox2 expression causes
down-regulation of the expression of a large number of Wnt
target genes, while inhibiting osteoblast differentiation.
 
Sox2 interferes with a 
 
 
 
-catenin–
dependent, Wnt-inducible promoter
 
To test whether or not Sox2 could repress Wnt–
 
 
 
-catenin–
induced gene expression, we assessed the effect of increasing
amounts of Sox2 on the expression of the TOPFLASH Wnt re-
porter plasmid. When TOPFLASH is cotransfected with a plas-
mid encoding a constitutively active form of 
 
 
 
-catenin (
 
 
 
N89), basal luciferase activity was strongly increased in 293
cells (Fig. 6 A). Cotransfection with increasing amounts of the
Sox2 encoding plasmid reduced the 
 
 
 
-catenin–induced activity
of TOPFLASH in a dose-dependent manner, whereas Sox2
alone had no effect on the basal activity of TOPFLASH (Fig. 6
A). A control plasmid (FOPFLASH) containing mutated TCF/
LEF sites was unaffected by cotransfection of active 
 
 
 
-catenin
or Sox2 (unpublished data).
To determine which domains of Sox2 were required for
the inhibition of TOPFLASH activity, we used mutants of Sox2
lacking the NH
 
2
 
 or COOH terminus of the protein. A deletion
mutant of Sox2 (31–319 aa), which lacks the first 31 amino
acids, can efficiently repress the 
 
 
 
-catenin–dependent TOP-
FLASH activity, whereas the 1–129 mutant, which contains
the HMG box and nuclear localization signals (Sudbeck and
Scherer, 1997) but is missing the COOH-terminal portion, can-
not. Furthermore, a Sox2 fragment (121–319 aa) containing
only the COOH-terminal portion of the protein could repress
TOPFLASH promoter activity when fused to the DNA binding
domain of the LexA protein, which contains a nuclear localiza-
tion signal (Fig. 6 B; Rhee et al., 2000). These experiments show
that the ability of Sox2 to interfere with a 
 
 
 
-catenin responsive
promoter containing TCF/LEF binding sites resides within the
COOH-terminal portion of Sox2 outside of the DNA binding
HMG domain. A similar result was obtained in OB1 osteoblasts
 
Table I. 
 
Expression changes in differentiation-associated genes in 
OB1 cells constitutively expressing Sox2 (clone Sox2#16)
OB1 OB1/diff Sox2#16 Sox2#16/diff
 
Up-regulated
osteocalcin L24431 1 3.45 0.63 0.71
decorin X53929 1 4.01 0.01 0.23
osteomodulin AB007848 1 15.57 2.93 6.80
osteoglycin D31951 1 26.67 2.77 26.13
C/EBP
 
 
 
M62362 1 8.17 0.37 0.56
IGFBP3 X81581 1 67.94 1.36 0.78
BMP4 X56848 1 6.76 2.70 3.22
fibromodulin X94998 1 12.41 0.38 0.09
cadherin-11 D21253 1 9.39 1.14 3.77
osf-2 D13664 1 125.3 1.25 6.23
Down-regulated
c-fos V00727 1 0.06 0.09 0.18
PCNA X57800 1 0.21 1.83 1.89
TK X60980 1 0.14 1.77 0.82
junB U20735 1 0.06 0.67 0.51
Krox-20/egr-2 M24377 1 0.22 0.18 0.33
Krox-24/egr-1 M28845 1 0.09 0.08 0.22
 
Biotinylated cRNAs were prepared from duplicate samples of undifferentiated
and differentiated Sox2#16 cells. Samples were hybridized to U74Av2 mouse
chips and scanned using the GeneArray scanner. Numbers represent the level
of gene expression normalized to that of OB1 cells. Fold changes were
calculated by the GeneSpring software averaged from the separate samples of
OB1, OB1/diff, and Sox2#16 and Sox2#16/diff. Normalizations were
performed as described in Materials and methods. Because the normalization
corrects for hybridization intensity across a set of chips in each experiment, the
values produced for OB1/diff samples in this experiment vary slightly from the
values in Fig. 1 A.
Figure 5. Wnt target genes are down-regulated in Sox2-expressing
osteoblasts. (A) Level of expression of Wnt target genes in Sox2#16 osteo-
blasts normalized to OB1. These data are derived from the same micro-
array analysis described in Table I. Normalizations were done as described
in Materials and methods. (B) Real-time PCR analysis of Wnt target genes
in osteoblast-expressing Sox2. Total RNA from OB1, OB1/vector, and
OB1/Sox2#16 cells was reverse transcribed amplified by real-time PCR
using SYBR green I for detection. For each PCR reaction, crosspoint values
for engrailed1 and connexin 43 were normalized using  -catenin values,
and relative expression level obtained for OB1 osteoblast (black bar)
was set as 100%. Each bar represents the mean of three independent
experiments   SD. 
JCB • VOLUME 168 • NUMBER 7 • 2005 1072
 
(unpublished data). Thus, although Sox2 HMG domain shares
homology with TCF/LEF factors and could potentially compete
for DNA binding, the repressive effect of Sox2 on a Wnt-induc-
ible promoter does not require its DNA binding activity.
 
Endogenous Sox2 associates with
 
 
 
-catenin in osteoblasts
 
We determined if Sox2 associates with 
 
 
 
-catenin in osteo-
blasts. We performed coimmunoprecipitation experiments on
lysates prepared from OB1, AP, or CR cells that were untreated
(
 
 
 
) or treated (
 
 
 
) with FGF. The cellular lysates were sub-
jected to immunoprecipitation with antibodies directed against
 
 
 
-catenin or Sox2. Fig. 6 D shows that Sox2 is detected in the
immunoprecipitate with 
 
 
 
-catenin in OB1 cells that are treated
with FGF, whereas in AP lysates, Sox2 is detected in the
 
 
 
-catenin immunoprecipitate both in untreated and FGF-
treated cells. In the reverse experiment, 
 
 
 
-catenin was detected
in immunoprecipitates of Sox2 only in OB1 cells treated with
FGF, whereas in AP cells it is seen in both FGF-treated or un-
treated samples. Thus, Sox2 coprecipitates with 
 
 
 
-catenin in
osteoblasts, an association that is clearly detected when Sox2
expression is induced by FGF. These data strongly suggest that
Sox2 interferes with Wnt responsive genes in osteoblasts by
sequestering nuclear 
 
 
 
-catenin and preventing its binding to
TCF/LEF factors.
 
Discussion
 
The experiments presented in this paper were undertaken to
provide a mechanistic explanation for the response of osteo-
blasts to FGF signaling, a response that must underlie the skel-
etal pathologies caused by excessive FGF signaling in these
cells. The most distinctive responses of osteoblasts in culture to
sustained FGF treatment or to the expression of activating
FGFR mutations are inhibition of differentiation and a high
rate of apoptosis when exposed to differentiating conditions.
These effects are osteoblast-specific as FGFs are generally
mitogenic and antiapoptotic growth factors. Therefore, we
Figure 6. Sox2 affects the Wnt pathway. (A) Schematic
representation of Sox2 constructs. (B) Sox 2 interferes with
the   -catenin–mediated activation of a TCF/LEF reporter
construct. 293 cells were transiently cotransfected with TOP-
FLASH, a stable  -catenin mutant ( N89), and increasing
amounts of wild-type Sox 2 and Sox2 mutants (40 ng) as
indicated. (C) Expression of the Sox2 constructs and of  -cat-
enin was verified by Western blotting of cell lysates using
antibodies against  -catenin, Sox2, or tubulin. (D) Sox2
associates with  -catenin in osteoblasts. 1 mg of whole cell
extracts (WCE) from untreated ( ) or cells treated with 10
ng/ml FGF1 for 24 h ( ) were immunoprecipitated (IP) with
antibodies against Sox2 or  -catenin and run on SDS PAGE.
Western blots were immunoblotted (IB) with the indicated
antibodies. 20  g of whole cell extracts from CR cells was
run as a control. 
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thought that the response of osteoblasts to FGF could be due to
a combination of direct FGF signals, a cell type–specific ability
to regulate the expression of particular genes, and cross-talk
with other signaling pathways.
Therefore, we analyzed the profiles of gene expression
under growing or differentiating conditions in an osteoblastic
cell line, OB1, and two isogenic derivatives expressing consti-
tutively active FGFR2. We also extended this analysis to cells
treated with exogenous FGF. Our results show that FGF signal-
ing in osteoblasts induces several changes in gene expression
that could explain, at least in part, the complex biological re-
sponse of these cells to FGF stimulation. Among these changes
we focused our attention on the down-regulation of Wnt target
genes and the induction of the transcription factor Sox2, and on
how these two events could influence osteoblast differentiation.
 
Expression of genes involved in 
osteoblast differentiation
 
The gene expression profiles of AP and CR cells compared
with OB1 in growing and differentiating conditions were gen-
erally consistent with the block in differentiation observed in
these cells by morphological criteria and ALP staining. For ex-
ample, it appears that the IGF signaling system, which is
known to induce osteoblast differentiation, is down-regulated
in AP and CR cells compared with OB1. Although this appears
to be the case also for BMP signaling, which also drives osteo-
blast differentiation, the effects of FGF on expression of genes
regulated by BMP signals in the microarray are less straightfor-
ward, and some BMP antagonists are also down-regulated.
Also, some BMP target genes may be indirectly affected due to
the differentiation block. The expression of several apoptosis-
related genes is altered in AP and CR cells consistent with their
increased apoptosis. Although it is still unclear how increased
apoptosis relates to osteoblast differentiation and bone forma-
tion, there are clear indications that it is increased in cranio-
synostosis and must play a role in modulating these processes
(Chen et al., 2003; Marie, 2003).
Of the transcription factor genes that have been shown to
be important for osteoblast physiology and pathologies, we
found that the expression of CbfaI (runx2), which is essential
for osteoblast commitment and differentiation (Karsenty and
Wagner, 2002), is unchanged in the AP and CR cells, both at
the RNA and protein level (unpublished data). Furthermore, we
observed down-regulation of msx2 mRNA, whose gain-of-
function mutations are linked to Boston-type craniosynostosis
(Wilkie, 1997). We also found no change in expression of the
transcription factor twist. Haploinsufficiency of twist is respon-
sible for Saethre-Chotzen type craniosynostosis, and it has
been suggested that FGF signaling and twist may lie in the
same pathway and that twist may regulate FGFR2 expression
as well as that of several FGF ligands (Wilkie, 1997; Rice et
al., 2000). Our results do not support the simple hypothesis
that excessive FGF signaling may produce craniosynostosis
through up-regulation of msx2, down-regulation of twist, or
down-regulation of Cbfa/Runx2 expression. Thus, cranio-
synostosis may be an endpoint that can be achieved by several
independent mechanisms.
 
Down-regulation of Wnt signaling by FGF
 
A significant proportion (40%) of Wnt target genes present on
the microarray chip are down-regulated in the AP and CR cells,
and treatment of OB1 cells with exogenous FGF elicited a sim-
ilar down-regulation. Because the expression of most genes is
subject to multiple transcriptional controls, it is not surprising
that not all Wnt target genes are down-regulated. Down-regula-
tion of some Wnt target genes could be counteracted by the ac-
tivation of other factors by FGF. Indeed, Wnt target genes such
as c-myc, fra-1, and cyclinD1, which are not down-regulated in
the AP and CR cells, are induced by FGF with early kinetics in
many cell types, including OB1 (unpublished data). Addition-
ally, the targets of Wnt–
 
 
 
-catenin signals may vary depending
on the cell type and FGF signals may down-regulate a much
higher proportion of Wnt target genes in osteoblasts.
Wnt signals are regulators of cell proliferation, differenti-
ation, and adhesion and are required to maintain the pluripotent
state of a variety of embryonic stem cells (Cadigan and Nusse,
1997; Lee et al., 2004). As discussed in the Introduction, recent
studies from human genetics and animal models have uncov-
ered a role for Wnt signaling in promoting osteoblast function
and bone formation, and Wnt signals cooperate with BMPs to
induce osteoblast differentiation (Rawadi et al., 2003), an ef-
fect that is opposite to that of the FGFs. Thus, down-regulation
of Wnt signaling could be an important mechanism by which
FGF inhibits osteoblast differentiation.
The FGFs and Wnts initiate signaling cascades that can
interact in a cooperative or antagonistic manner, depending on
the cell and tissue type. Cooperation between the FGF and Wnt
pathways is seen in mesoderm patterning, the developing limb,
neural crest induction, and the tooth bud (Ciruna and Rossant,
2001; Kawakami et al., 2001; Kratochwil et al., 2002). In con-
trast, in bone development, FGFs and Wnts appear to have op-
posing roles. Wnt signals promote osteoblast differentiation
and bone formation, whereas FGF signals inhibit osteoblast
differentiation. Furthermore, activation of Wnts protects from
apoptosis (Longo et al., 2002), and therefore, FGFs may in-
crease apoptosis in osteoblasts by antagonizing Wnt signals.
Although the mechanisms underlying these interactions are un-
known, they could be due to cell type–specific factors that me-
diate the cross-talk between these signaling pathways. We
identified one such mediator, the FGF-inducible transcription
factor Sox2, that can block osteoblast differentiation and inter-
fere with Wnt signaling.
 
Role of Sox2 in osteoblast 
differentiation and down-regulation of 
Wnt target genes
 
Given the documented role of Sox2 in maintaining the undif-
ferentiated state of cells, and that it is expressed in the neural
crest (Wakamatsu et al., 2004), from which calvarial osteo-
blasts are derived, we reasoned that the induction of Sox2 by
FGF could be important in inhibiting osteoblast differentiation.
The induction of Sox2 by FGF occurs in variety of osteoblastic
cells, but not in fibroblasts or chondrocytes. This cell-type re-
striction may be due to osteoblast-specific signal transduction
pathways, unique transcription factors, and/or to an “active” 
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chromatin configuration at the Sox2 locus in osteoblasts. The
induction of Sox2 by FGF has also recently been reported in
lens regeneration in the newt (Hayashi et al., 2004). We have
shown that ectopic expression of Sox2 in OB1 or OB5 osteo-
blasts inhibits their ability to differentiate. Previous analysis of
Sox2 expression in the developing mouse embryo (Avilion et
al., 2003) did not report Sox2 expression in cranial osteoblasts.
Here, we show that Sox2 is expressed in the calvarial bone os-
teogenic fronts, an area that corresponds to high FGFR2 activ-
ity. Furthermore, we have obtained primary calvarial osteo-
blasts from Sox2 
 
 
 
/
 
 
 
 heterozygous animals (Avilion et al.,
2003) and found that they differentiate faster than osteoblasts
from littermate control animals (unpublished data). Thus, os-
teoblast differentiation may be accelerated by a reduction in the
level of Sox2.
The mechanism by which Sox2 inhibits osteoblast differ-
entiation appears to reside, at least in part, in its ability to in-
hibit Wnt–
 
 
 
-catenin signaling. We showed that Sox2 associ-
ates with 
 
 
 
-catenin in FGF-stimulated osteoblasts and can
repress the activity of a reporter plasmid driven by 
 
 
 
-catenin–
TCF/LEF binding sites. Furthermore, osteoblasts constitutively
expressing Sox2, like cells expressing activated FGFR2, down-
regulate the expression of multiple Wnt target genes.
In mammals, the Sox family of transcription factors com-
prises 20 members, which share a single HMG domain that
binds specifically to variations of a consensus DNA sequence.
In its function as a transcription factor, Sox2 synergizes with
different protein partners to direct cell type–specific gene ex-
pression (Ambrosetti et al., 2000; Kamachi et al., 2000; Dailey
and Basilico, 2001). Thus, it is possible that Sox2 may down-
regulate Wnt genes by partnering with unidentified cofactors,
as is the case for Sox17, which partners with 
 
 -catenin to acti-
vate transcription of endoderm-specific genes (Sinner et al.,
2004). Sox factors are distantly related to the TCF/LEF-1 fam-
ily, which bind to similar consensus sequences, and thus Sox
factors could compete directly for DNA binding with TCF/LEF
(Haremaki et al., 2003).
An alternate function for Sox factors in inhibiting Wnt
signaling was demonstrated by Zorn et al. (1999), who showed
that Sox3 and Sox17 could repress  -catenin–stimulated gene
expression in X. laevis and physically interact with  -catenin in
vitro. Subsequently, other Sox factors have been reported to in-
terfere with  -catenin–induced transcription (Kan et al., 2004).
The inhibitory activity of Sox3 and Sox17 on a Wnt-inducible
reporter gene was contained in the COOH terminus (Zorn et
al., 1999). We also found that the region of Sox2 that inhibited
the  -catenin–inducible TOPFLASH promoter was contained
in the COOH terminus and did not require the Sox2 DNA-
binding domain, supporting the notion that the major mecha-
nism by which Sox2 inhibits Wnt signaling does not involve its
classical function as a transcription factor.
Although Sox17 shares little homology with Sox2 in the
COOH terminus, it is conceivable that they both bind to the ar-
madillo repeats of  -catenin that can interact with diverse
ligands at conserved noncontiguous epitopes (Daniels and
Weis, 2002). This motif is also present in the Sox2 COOH ter-
minus (unpublished data). In chondrocytes, Sox9 inhibits Wnt
signaling by competing with TCF/LEF for  -catenin binding
and enhancing the degradation of  -catenin (Akiyama et al.,
2004). However, the effect of Sox2 on Wnt signaling in osteo-
blasts does not appear to be due to the degradation of  -catenin.
Implications for FGF-induced 
craniosynostosis
Craniosynostosis is a heterogeneous developmental skeletal
disorder that can lead to a variety of abnormalities including
abnormal head shape, proptosis, and mental retardation. The
results presented in this paper suggest a mechanism by which
excessive FGFR2 signaling, through a combination of direct
and indirect effects, could induce premature suture fusion. The
initial response to FGF of immature osteoblast/osteoprogenitor
cells is increased proliferation. This response would cause an
expansion of the cell population entering the differentiation
pool and accelerate suture closure. As these cells mature and
differentiate, they would have to modulate the expression of
the genes involved in osteoblast function, many of which are
under the control of Wnt signaling, as well as slow down their
growth. The block to Wnt signaling induced by FGF would
prevent such events, and thus osteoblast differentiation. As also
shown by our data, this block is not complete, and thus stochas-
tically, the expanded osteoblast population would still be able
to lay down bone matrix and create bone, a process facilitated
by the down-regulation of FGFR2 expression that occurs be-
hind the osteogenic fronts, as cells differentiate (Iseki et al.,
1999). The high rate of apoptosis observed in vitro and in vivo
in differentiating osteoblasts with constitutive FGFR2 signal-
ing could represent the response of cells that have lost their
ability to arrest proliferation when subjected to growth-inhibit-
ing signals. Apoptosis could be promoted by the modulation
of the expression of apoptosis-regulating molecules such as
GAS6, wisp1, and bid (Fig. 1) that are induced by down-regu-
lation of Wnt signaling and/or constitutive FGF signaling.
In summary, these results indicate that FGF signaling ac-
tivates or represses a network of transcriptional events in osteo-
blasts, which includes induction of Sox2 and down-regulation
of Wnt signaling. Both of these effects are likely to be impor-
tant mechanisms by which FGF affects the ability of these cells
to differentiate. Our results also suggest that early pharmaco-
logical interventions that would boost Wnt signaling could
perhaps ameliorate the craniofacial defects of patients with
FGFR2 mutations.
Materials and methods
Cell culture and preparation of primary osteoblasts
Cells were grown in DME (GIBCO BRL) containing 10% FCS. Primary calva-
rial osteoblasts were prepared as previously described (Mansukhani et al.,
2000). For differentiation of osteoblasts, cells were cultured for up to 21 d
in growth media containing 50  g/ml ascorbic acid and 4 mM  -glycero-
phosphate and the medium was changed every 3 d. Sox2 mutant osteo-
blasts were a gift of S. Nicolis (University of Milan-Bicocca, Milan, Italy).
Microarray analysis
Total RNA was prepared from three independent replicates of each sam-
ple using Trizol (GIBCO BRL). Biotinylated cRNA was prepared from 10
 g RNA as detailed according to the protocol (Affymetrix, Inc.), hybrid-
ized to U74Av2 mouse genome array, and scanned by the GeneArrayFGF REGULATES WNT IN OSTEOBLAST DIFFERENTIATION • MANSUKHANI ET AL. 1075
Scanner (Affymetrix, Inc.) at the Columbia University Microarray Facility
(New York, NY). Metrics files were generated from each chip using Mi-
croarray Suite 5.0 (Affymetrix, Inc.). The U74Av2 arrays contain probes
for  9,400 genes including  3,700 EST clusters. Further analysis was
performed in the GeneSpring 5.0 (Silicon Genetics) as detailed previously
(Dailey et al., 2003). Genes that did not exhibit a minimum raw signal of
100 in at least one sample were filtered out. Genes were classified as ex-
pressed in a given experiment if they were flagged as present in at least
one sample. The value for each gene’s expression was normalized across
all of the chips using 50% of all measurements as a positive control. The
measurement for each gene was divided by this value (per chip normal-
ization). Background correction was made using the lower 10% (per gene
normalization). The values from multiple points in each sample were aver-
aged and used for comparative analysis. Genes with  2.5–fold changes
in gene expression were identified using Venn Diagrams of expressed
genes in each sample.
ALP and Alizarin red staining
Cells were fixed with citrate/methanol for 1 min at RT, and histochemical
ALP staining was performed according to manufacturer’s instructions
(Sigma-Aldrich). To detect mineralized nodules, Alizarin red S (75  g/ml)
was left on the plates overnight and washed with water.
PCR analysis
Total RNA was extracted using TRIzol Reagent (Invitrogen), treated with
DNase, and purified using the Rneasy mini kit (QIAGEN) according to the
manufacturer’s protocol. 0.5–2  g of purified RNA was reverse transcribed
at 42 C for 1 h using 50 U of SuperScript II RT and Oligo(dT) as a primer in
a final volume of 20  l. 1–2  l of cDNA was used as a template for ampli-
fication by PCR. Real-time quantitative PCRs were performed in a Light Cy-
cler Instrument using the DNA Master SYBR Green I dye intercalation assay
(Roche). Primers were designed using the Oligo Primer Analysis software.
Primers were generally chosen to amplify 150–250-bp amplicons in the 3 
untranslated region of the gene. For each amplified cDNA, crossing point
values for different sample were determined by fluorescent monitoring and
transformed to relative amounts of mRNA by comparison with the cross-
ing point value obtained for the control OB1 cells. In some experiments,
 -catenin expression levels were used as reference for normalization.
Immunoprecipitation and Western blot analysis
Cells were treated with 10 ng/ml FGF1 and 5  g/ml heparin for 24 h in
DME containing 10% FCS. Cells were rinsed in PBS and lysed in RIPA buffer
(10 mM Tris/HCl, pH 7.2, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 1% Na
Deoxycholate, and 1% Triton X-100) containing protease and phosphatase
inhibitors. 0.75–1 mg of protein extracts were immunoprecipitated with spe-
cific antibodies, and proteins were visualized as previously described (Man-
sukhani et al., 2000). Antibodies against Sox2 were purchased from
Chemicon International and anti– -catenin from BD Biosciences.
Expression of Sox2 in OB1 cells and reporter assays in 293 cells
Full-length Sox2 and Sox2 deletion mutants expression plasmids have
been previously described (Ambrosetti et al., 2000). Transfection in OB1
or OB5 cells was done using Lipofectamine 2000 (GIBCO BRL). Colonies
were selected in 200  g/ml hygromycin (GIBCO BRL). TOPFLASH, FOP-
FLASH (Korinek et al., 1997), and  N89 -catenin were a gift from
L. Howe (Strang Cancer Prevention Center, New York, NY). Typically,
HEK293 cells in 24-well plates were transfected with 100 ng TOPFLASH,
20 ng  N89 -catenin, and up to 40 ng of Sox2-expressing plasmids us-
ing Superfect Transfection Reagent (QIAGEN; HEK293) as described by
the manufacturer. After 48 h, cell lysates were prepared and assayed for
luciferase activity using the Promega Luciferase Assay System.
In situ hybridization
In situ hybridization was performed as described by Holmes and Niswander
(2001) using RNA antisense riboprobes labeled with digoxigenin-UTP.
Image acquisition
Images were viewed on Telaval 31 (for plates; Carl Zeiss MicroImaging,
Inc.) or Axioplan 2 (for slides; Carl Zeiss MicroImaging, Inc.) using 5 or
40  objectives. Digital images were acquired with an Axiocam camera
and Axiovision 2.0 software (Carl Zeiss MicroImaging, Inc.).
Online supplemental material
Figs. S1 and S2 show that LiCl treatment promotes differentiation of OB1,
OB1/AP, and OB5 osteoblasts. Online supplemental material is available
at http://www.jcb.org/cgi/content/full/jcb.200409182/DC1.
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